Palatin Technologies (PTN) Other financing activities (2014 - 2026)
Palatin Technologies' (PTN) quarterly Other financing activities came in at $139510.0 in Q1 2026, up 65091.59% YoY from N/an in Q1 2025, and down 87.66% on a QoQ basis from $1.1 million in Q4 2025.
Palatin Technologies (PTN) Other financing activities (2014 - 2026) Analysis & Trends
Palatin Technologies (PTN) has 9 years of Other financing activities data on file, last reported at $139510.0 in Q1 2026.
- Quarterly Other financing activities rose 65091.59% year-over-year to $139510.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 million (down 73.56% YoY) and the FY2025 annual result came in at $3.4 million, down 43.79% from the prior year.
- Other financing activities fell to $139510.0 in Q1 2026, from $1.1 million in the prior quarter.
- In the past five years, Other financing activities ranged from a high of $6.0 million in Q2 2024 to a low of -$263868.0 in Q1 2022.
- A 5-year average of $955534.1 and a median of $201689.0 in 2022 frame the typical range for Other financing activities.
- Annual changes were most pronounced in 2023 — Other financing activities jumped 100.03% — and 2026, when it soared 65091.59%.
- Tracing PTN's Other financing activities over 5 years: stood at $263868.0 in 2022, then tumbled by 99.97% to $78.0 in 2023, then soared by 7750591.03% to $6.0 million in 2024, then tumbled by 81.3% to $1.1 million in 2025, then sank by 87.66% to $139510.0 in 2026.
- The last three Other financing activities figures came in at $139510.0 (Q1 2026), $1.1 million (Q4 2025), and $328200.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Palatin Technologies | 40.37 Mn | 40.37 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 139,510.00 |
| Mar 31, 2026 | 139,510.00 |
| Dec 31, 2025 | 1.13 Mn |
| Dec 31, 2025 | 1.13 Mn |
| Sep 30, 2025 | 328,200.00 |
| Sep 30, 2025 | 328,200.00 |
| Mar 31, 2025 | 214.00 |
| Mar 31, 2025 | 214.00 |
| Jun 30, 2024 | 6.05 Mn |
| Jun 30, 2024 | 6.05 Mn |
| Mar 31, 2023 | 78.00 |
| Mar 31, 2023 | 78.00 |
| Jun 30, 2022 | 263,868.00 |
| Jun 30, 2022 | 263,868.00 |
| Mar 31, 2022 | -263,868.00 |
| Mar 31, 2022 | -263,868.00 |
| Jun 30, 2018 | 2.48 Mn |
| Jun 30, 2018 | 2.48 Mn |
| Mar 31, 2018 | -83,153.00 |
| Mar 31, 2018 | -83,153.00 |